Form 4: TransMedics Group Executive Tamer Khayal Executes Stock Option and Sells Shares
SEC Form 4 Filing
TransMedics Group's Chief Commercial Officer, Tamer Khayal, exercised stock options and sold shares on December 2, 2024, under a pre-arranged trading plan.
Summary
- Tamer Khayal, Chief Commercial Officer of TransMedics Group, executed a stock option to acquire 1,084 shares of common stock at a price of $13.28 per share on December 2, 2024.
- Concurrently, Mr. Khayal sold 1,084 shares of common stock at a weighted average price of $86.4, with individual sales ranging from $86.21 to $86.89.
- These transactions were conducted under a Rule 10b5-1 trading plan established on September 6, 2023.
- Following these transactions, Mr. Khayal directly owns 20,843 shares of TransMedics Group common stock and 16,250 stock options.
Sentiment
Score: 5
Explanation: The document reflects routine insider trading activity under a pre-arranged plan, which is neither positive nor negative for the company's overall outlook.
Industry Context
This is a routine filing related to insider trading activity and is common for executives of publicly traded companies. The use of a 10b5-1 plan is a common practice to avoid accusations of insider trading.
Comparison to Industry Standards
- The use of Rule 10b5-1 trading plans is a standard practice among publicly traded companies to allow insiders to sell shares without being accused of trading on non-public information.
- The vesting schedule of the options is typical for executive compensation packages, with a monthly vesting rate until fully vested.
- The price range of the share sales is within the normal trading range for the stock at the time of the transaction.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are part of a pre-arranged trading plan and do not indicate a change in the executive's long-term view of the company.
Key Dates
| Date | Description |
|---|---|
| 09/06/2023 | Date the Rule 10b5-1 trading plan was established. |
| 12/02/2024 | Date of the stock option exercise and share sale. |
| 02/22/2026 | Date the stock options are fully vested. |
| 02/22/2032 | Expiration date of the stock options. |
| 12/04/2024 | Date the Form 4 was signed. |
Keywords
TransMedics Group, Tamer Khayal, stock options, share sale, Rule 10b5-1, insider trading, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.